Page 7 - PD-L1 EbookV2 Flip PDF
P. 7
planning and implementation on the majority of biomarkers is underestimated, under-
budgeted and under-resourced
References
1. Diaceutics’ Pharma Readiness for Diagnostic Integration 2017
2. FDA Review Process for Companion Diagnostic Devices (Soma Ghosh, Tri-Con presentation 2017)
3. Diaceutics webinar February 2017, What are the major differences in biomarker test adoption in European
countries? An analysis of PD–L1 testing in Italy and Germany
4. Diaceutics’ Longitudinal Panel of PD-L1 Testing Behaviour Among Prescribers. (This panel leverages an
analysis of the same 20 Opdivo/Keytruda prescribers in NSCLC to track shifting perceptions over time.)
Originally published at diaceutics.com, 25 May 2017
Page 7 of 31
